Healthy Inc > Products > Alfuzosin Tablets

Alfuzosin Hydrochloride Extended-Release Tablets (10 mg)

Healthy Inc is a specialized global supplier and exporter of advanced urology, nephrology, and targeted internal medicine therapeutics. We provide ultra-high-purity, kinetically optimized Alfuzosin ER Tablets, manufactured in WHO–GMP certified, high-precision specialized oral solid dosage facilities. This “Uro-selective Alpha-1 Adrenergic Antagonist” is a massive-volume strategic export to urology hospitals, men’s health clinics, and government health ministries, serving as the globally preferred first-line intervention for Benign Prostatic Hyperplasia (BPH).

Product Overview

This formulation operates as a “Mechanical Relief Valve.” It is specifically engineered to relax the physical obstruction caused by an enlarged prostate without significantly affecting systemic blood pressure.

  • Mechanism 1 (Uro-Selective Alpha-Blockade): Alfuzosin selectively binds to Alpha-1 Adrenoreceptors located in the smooth muscle of the prostate, the prostatic capsule, and the bladder neck. By blocking these receptors, it physically relaxes the muscle tension.

  • Mechanism 2 (Improved Urodynamics): As the muscle relaxes, the resistance to urine flow through the urethra is decreased. This provides Rapid Relief from symptoms such as hesitancy, weak stream, and incomplete emptying.

  • Mechanism 3 (The Extended-Release Advantage): Our “ER” technology utilizes a specialized hydrophilic matrix. This ensures the drug is released slowly over 24 hours, maintaining a steady plasma concentration and significantly reducing the risk of “First-Dose Hypotension” (sudden dizziness).

Product Composition & Strength

We supply this product as a Precision-Blended, Extended-Release (ER) Tablet, packed in high-barrier Alu-Alu blister strips to ensure API stability.

Active IngredientStrengthPrimary Clinical Function
Alfuzosin Hydrochloride USP/BP10 mgThe Standard Therapeutic Anchor: The globally validated once-daily dose for moderate-to-severe BPH symptoms.
ExcipientsExtended-Release MatrixControlled-Delivery System: Engineered to provide synchronized 24-hour therapeutic coverage, eliminating the need for multiple daily doses.

Technical & Logistics Specifications

  • HS Code: 3004.90.99 (Medicaments acting on the Urinary System – Alpha Blockers)

  • CAS Number: 81403-68-1 (Alfuzosin Hydrochloride)

  • Dosage Form: Extended-Release (ER) / Prolonged-Release Tablet

  • Packaging: Alu-Alu Blisters. Protects the API from environmental humidity; our moisture-lock packaging ensures 24-month stability in Zone IVb tropical climates.

Manufacturing Authority & Compliance

  • Uro-Selective Purity: Our manufacturing process focuses on absolute chemical purity to ensure the Alpha-1a vs. Alpha-1b selectivity remains exact, providing the superior cardiovascular safety profile required for elderly patients.

  • Bioequivalence Integrity: We provide comprehensive dissolution profiles (0–24 hours) to prove our generic matches the pharmacokinetic curve of the innovator brand (Uroxatral/Xatral), ensuring reliable clinical outcomes.

Primary Indications

  • Urology: Treatment of the functional symptoms of Benign Prostatic Hyperplasia (BPH).

  • Acute Care: Adjunctive therapy for Acute Urinary Retention (AUR) related to BPH, often used alongside catheterization to improve the success of “Trial Without Catheter” (TWOC).

  • Men’s Health: Management of Lower Urinary Tract Symptoms (LUTS) to improve quality of life and sleep (reducing nocturia).

Dosage & Administration

  • Standard Adult Dosing: One 10 mg tablet once daily.

  • Administration: Must be taken immediately after a meal (the same meal every day). Food significantly increases the absorption and bioavailability of Alfuzosin.

  • Important: Tablets must be swallowed whole; do not crush or chew, as this would release the 24-hour dose instantly.

Safety Warning: Orthostatic Hypotension. Although more selective than older drugs, patients should be monitored for dizziness or fainting upon standing. QT Prolongation: Use with caution in patients with a known history of QT interval prolongation. Strictly contraindicated in patients with moderate-to-severe hepatic impairment or those taking potent CYP3A4 inhibitors.

Global Export & Contract Manufacturing

Healthy Inc is a premier Urology Pharmaceutical Exporter in India. As a verified Medicine Supplier in Mumbai, we offer flexible Third Party Manufacturing (Contract Manufacturing) for high-volume BPH therapeutics. Whether you are a Men’s Health Clinic Network in Africa or a B2B Pharma Marketplace partner in the CIS, we ensure secure, WHO-GMP compliant delivery.

Add to cart